Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs ProShares UltraPro S&P500 — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5 (market cap $1.74B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: ProShares UltraPro S&P500 is far larger — about 3.2× Nuvation Bio Inc. Class A Common Stock's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 1 Days and ProShares UltraPro S&P500 for 29 Days on average.
| NUVB | UPRO | |
|---|---|---|
Market Cap | $1.74B | $5.55B |
Volume | 9,289,619 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $9.54 | $157.66 |
52-Week Low | $3.41 | $89.29 |
Typical Hold Time | 1 Days | 29 Days |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $153.19, down 1.3% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The stock faces resistance at $155 and support at $151. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment around the broader market environment.
The outlook for UPRO is influenced by broader market dynamics, with Wall Street expecting continued S&P 500 gains but facing headwinds from concentration risks and economic uncertainty. Key opportunities include potential year-end rallies, while risks involve market volatility and earnings growth slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
